F.D.A. Moves to Speed Approvals for Cheaper Copycat Drugs
F.D.A. Moves to Speed Approvals for Cheaper Copycat Drugs
The agency announced moves to cut regulatory obstacles for the makers of biosimilar drugs, which are akin to generics and may help lower drug costs.
Read the full article on NY Times Politics
Truth Analysis
Analysis Summary:
The article is mostly accurate, focusing on the FDA's efforts to expedite biosimilar drug approvals. The article exhibits a slight bias by framing the FDA's actions as beneficial for lowering drug costs, without exploring potential downsides or alternative perspectives. The core claim is supported by multiple sources.
Detailed Analysis:
- Claim: The FDA is moving to cut regulatory obstacles for makers of biosimilar drugs.
- Verification Source #1: Confirms the FDA is moving to ease the path for biosimilars, making it quicker and cheaper to win approval.
- Verification Source #3: Supports the idea that the FDA wants to speed up approvals for new drugs, including copycat drugs.
- Assessment: Supported
- Claim: Biosimilar drugs are akin to generics and may help lower drug costs.
- Verification Source #1: States the proposal would make it quicker and cheaper to win approval for copies of biologic drugs, implying a cost reduction.
- Verification Source #5: Mentions FDA Commissioner Scott Gottlieb's push to speed up approval of copycat drugs to foster competition, which could lead to lower prices.
- Assessment: Supported
Supporting Evidence/Contradictions:
- Source 1: Proposal would make it quicker and cheaper to win approval for copies of biologic drugs
- Source 3: Officials at the FDA say they want to speed up approvals for new ... copycat drug sales, and more.